JAGX
Jaguar Health, Inc. [JAGX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
JAGX Stock Summary
Top 10 Correlated Stocks
JAGX
In the News
JAGX Financial details
Company Rating
Neutral
Market Cap
18.67M
Income
-41.3M
Revenue
9.76M
Book val./share
0.07
Cash/share
0.09
Dividend
-
Dividend %
-
Employees
49
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-0.06
Forward P/E
-
PEG
0.01
P/S
0.56
P/B
1.81
P/C
1.8
P/FCF
-0.19
Quick Ratio
0.41
Current Ratio
1.77
Debt / Equity
7.3
LT Debt / Equity
6.33
-
-
EPS (TTM)
-3.59
EPS next Y
-
EPS next Q
-
EPS this Y
-95.05%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-74.76%
Revenue last 5Y
11.07%
Revenue Q/Q
-18.24%
EPS Q/Q
-65.79%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-87%
ROE
-1154%
ROC
-1%
Gross Margin
83%
Oper. Margin
-308%
Profit Margin
-369%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.051-1.22
52W High
-
52W Low
-
RSI
66
Rel Volume
0.56
Avg Volume
45.24M
Volume
25.48M
Perf Week
50.7%
Perf Month
98.77%
Perf Quarter
-50.15%
Perf Half Y
-51.94%
-
-
-
-
Beta
1.383
-
-
Volatility
0.03%, 0.04%
Prev Close
-8.53%
Price
0.162
Change
12.34%
JAGX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 261.7 | 54.64 | 7.27 | 9.12 | 0.42 | |
| Net income per share | -1.75K | -214.22 | -101.07 | -36.18 | -1.79 | |
| Operating cash flow per share | -926.99 | -88.96 | -58.66 | -25.24 | -1.44 | |
| Free cash flow per share | -926.99 | -89 | -58.67 | -26.52 | -1.44 | |
| Cash per share | 158.39 | 47.1 | 28.6 | 4.17 | 0.28 | |
| Book value per share | 483.67 | 100.16 | 19.48 | -0.5 | 0.22 | |
| Tangible book value per share | -695.59 | -41.54 | -18.11 | -18.14 | -0.66 | |
| Share holders equity per share | 483.67 | 100.16 | 19.48 | -0.5 | 0.22 | |
| Interest debt per share | 602.49 | 110.64 | 63.38 | 36.26 | 1.29 | |
| Market cap | 3.98M | 31.49M | 46.5M | 8.56M | 3.49M | |
| Enterprise value | 8.05M | 39.61M | 58.81M | 37.93M | 34.12M | |
| P/E ratio | -0.1 | -0.86 | -0.77 | -0.18 | -0.08 | |
| Price to sales ratio | 0.69 | 3.36 | 10.73 | 0.72 | 0.36 | |
| POCF ratio | -0.19 | -2.06 | -1.33 | -0.26 | -0.11 | |
| PFCF ratio | -0.19 | -2.06 | -1.33 | -0.25 | -0.11 | |
| P/B Ratio | 0.37 | 1.83 | 4 | -13.04 | 0.7 | |
| PTB ratio | 0.37 | 1.83 | 4 | -13.04 | 0.7 | |
| EV to sales | 1.39 | 4.22 | 13.57 | 3.17 | 3.5 | |
| Enterprise value over EBITDA | -0.35 | -1.64 | -1.48 | -1.22 | -1.08 | |
| EV to operating cash flow | -0.39 | -2.59 | -1.68 | -1.15 | -1.03 | |
| EV to free cash flow | -0.39 | -2.59 | -1.68 | -1.09 | -1.03 | |
| Earnings yield | -9.69 | -1.17 | -1.3 | -5.54 | -11.83 | |
| Free cash flow yield | -5.14 | -0.49 | -0.75 | -4.06 | -9.52 | |
| Debt to equity | 0.71 | 0.94 | 2.53 | -53.02 | 7.3 | |
| Debt to assets | 0.21 | 0.38 | 0.55 | 0.73 | 0.71 | |
| Net debt to EBITDA | -0.18 | -0.34 | -0.31 | -0.94 | -0.97 | |
| Current ratio | 0.62 | 1.35 | 1.84 | 0.74 | 2 | |
| Interest coverage | -4.35 | -7.63 | -4.64 | -2.7 | 5.31 | |
| Income quality | 0.53 | 0.45 | 0.66 | 0.67 | 0.8 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 2.34 | 1.53 | 3.95 | 1.49 | 1.7 | |
| Research and developement to revenue | 1.01 | 0.68 | 3.48 | 1.48 | 1.91 | |
| Intangibles to total assets | 0.71 | 0.57 | 0.43 | 0.47 | 0.4 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0.05 | 0 | |
| Capex to revenue | 0 | 0 | 0 | -0.14 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | -0.73 | 0 | |
| Stock based compensation to revenue | 0.52 | 0.3 | 0.92 | 0.28 | 0.22 | |
| Graham number | 4.36K | 694.81 | 210.45 | 20.19 | 2.94 | |
| ROIC | -1.34 | -0.69 | -1.06 | -0.95 | -0.79 | |
| Return on tangible assets | -3.71 | -1.99 | -1.97 | -1.9 | -1.35 | |
| Graham Net | -902.04 | -74.18 | -34.06 | -28.96 | -1.44 | |
| Working capital | -5.87M | 4.57M | 12.96M | -8.02M | 13.98M | |
| Tangible asset value | -15.35M | -7.14M | -10.8M | -23.8M | -15.22M | |
| Net current asset value | -16.21M | -7.85M | -12.98M | -26.49M | -17.9M | |
| Invested capital | 0.71 | 0.94 | 2.53 | -53.02 | 7.3 | |
| Average receivables | 1.35M | 3.13M | 3.35M | 2.31M | 2.33M | |
| Average payables | 5.38M | 5.06M | 4.84M | 5.37M | 5.39M | |
| Average inventory | 2.74M | 2.46M | 3.84M | 5.96M | 8.11M | |
| Days sales outstanding | 107.1 | 177.35 | 180.52 | 75.31 | 81.67 | |
| Days payables outstanding | 511.9 | 529.58 | 771.15 | 1.05K | 410.28 | |
| Days of inventory on hand | 203.62 | 309.58 | 766.61 | 1.27K | 757.96 | |
| Receivables turnover | 3.41 | 2.06 | 2.02 | 4.85 | 4.47 | |
| Payables turnover | 0.71 | 0.69 | 0.47 | 0.35 | 0.89 | |
| Inventory turnover | 1.79 | 1.18 | 0.48 | 0.29 | 0.48 | |
| ROE | -3.61 | -2.14 | -5.19 | 72.23 | -8.32 | |
| Capex per share | 0 | -0.04 | -0.01 | -1.28 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.47 | 0.39 | 0.15 | 0.14 | 0.03 | |
| Net income per share | -3.34 | -2.39 | -0.69 | -0.38 | -0.13 | |
| Operating cash flow per share | -2.91 | -1.95 | -0.51 | -0.33 | -0.1 | |
| Free cash flow per share | -3.07 | -1.95 | -0.51 | -0.33 | -0.1 | |
| Cash per share | 2.47 | 2.81 | 0.49 | 0.16 | 0.09 | |
| Book value per share | -0.3 | 1.44 | 0.32 | 0.07 | 0.07 | |
| Tangible book value per share | -10.76 | -2.8 | -0.89 | -0.94 | 0.07 | |
| Share holders equity per share | -0.3 | 1.44 | 0.32 | 0.07 | 0.07 | |
| Interest debt per share | 16.95 | 7.14 | 1.99 | 1.74 | 0.5 | |
| Market cap | 14.43M | 3.21M | 9.1M | 5.39M | 11.07M | |
| Enterprise value | 43.8M | 23.14M | 32.13M | 37.71M | 41.7M | |
| P/E ratio | -0.49 | -0.07 | -0.19 | -0.17 | -0.3 | |
| Price to sales ratio | 4.43 | 1.63 | 3.4 | 1.92 | 4.81 | |
| POCF ratio | -2.25 | -0.32 | -1 | -0.79 | -1.49 | |
| PFCF ratio | -2.13 | -0.32 | -1 | -0.79 | -1.49 | |
| P/B Ratio | -21.97 | 0.44 | 1.61 | 3.96 | 2.23 | |
| PTB ratio | -21.97 | 0.44 | 1.61 | 3.96 | 2.23 | |
| EV to sales | 13.44 | 11.73 | 12.01 | 13.41 | 18.13 | |
| Enterprise value over EBITDA | -10.13 | -2.49 | -4.31 | -4.58 | -6.32 | |
| EV to operating cash flow | -6.82 | -2.33 | -3.55 | -5.55 | -5.6 | |
| EV to free cash flow | -6.46 | -2.33 | -3.55 | -5.55 | -5.6 | |
| Earnings yield | -0.51 | -3.8 | -1.34 | -1.44 | -0.83 | |
| Free cash flow yield | -0.47 | -3.1 | -1 | -1.26 | -0.67 | |
| Debt to equity | -53.02 | 4.67 | 5.62 | 26.13 | 7.3 | |
| Debt to assets | 0.73 | 0.6 | 0.61 | 0.78 | 0.71 | |
| Net debt to EBITDA | -6.79 | -2.14 | -3.09 | -3.93 | -4.64 | |
| Current ratio | 0.74 | 1.04 | 0.97 | 1.77 | 2 | |
| Interest coverage | -2.39 | -4.51 | -2.35 | -17.57 | -28.98 | |
| Income quality | 0.72 | 0.79 | 0.75 | 0.85 | 0.81 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.92 | 2.44 | 1.92 | 1.55 | 0 | |
| Research and developement to revenue | 1.32 | 2.42 | 1.6 | 2.16 | 1.51 | |
| Intangibles to total assets | 0.47 | 0.39 | 0.41 | 0.46 | 0 | |
| Capex to operating cash flow | 0.06 | 0 | 0 | 0 | 0 | |
| Capex to revenue | -0.11 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.6 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0.15 | 0.24 | 0.2 | 0.19 | 0 | |
| Graham number | 4.73 | 8.79 | 2.23 | 0.74 | 0.44 | |
| ROIC | -0.16 | -0.23 | -0.21 | -0.24 | -0.17 | |
| Return on tangible assets | -0.3 | -0.35 | -0.4 | -0.32 | -0.18 | |
| Graham Net | -17.18 | -5.77 | -1.84 | -1.7 | -0.45 | |
| Working capital | -8.02M | 1.27M | -776K | 9.6M | 13.98M | |
| Tangible asset value | -23.8M | -14.29M | -15.64M | -19.56M | 4.9M | |
| Net current asset value | -26.49M | -16.91M | -18.12M | -21.91M | -17.9M | |
| Invested capital | -53.02 | 4.67 | 5.62 | 26.13 | 7.3 | |
| Average receivables | 2.46M | 1.96M | 1.5M | 1.7M | 2.01M | |
| Average payables | 6.05M | 5.75M | 5.18M | 4.9M | 5.05M | |
| Average inventory | 6.81M | 7.85M | 8.47M | 8.32M | 8.78M | |
| Days sales outstanding | 68.11 | 65.9 | 52.4 | 59.03 | 85.46 | |
| Days payables outstanding | 1.06K | 1.48K | 854.73 | 898.77 | 350.28 | |
| Days of inventory on hand | 1.28K | 2.27K | 1.51K | 1.47K | 647.11 | |
| Receivables turnover | 1.32 | 1.37 | 1.72 | 1.52 | 1.05 | |
| Payables turnover | 0.09 | 0.06 | 0.11 | 0.1 | 0.26 | |
| Inventory turnover | 0.07 | 0.04 | 0.06 | 0.06 | 0.14 | |
| ROE | 11.23 | -1.66 | -2.16 | -5.72 | -1.85 | |
| Capex per share | -0.16 | 0 | 0 | 0 | 0 |
JAGX Frequently Asked Questions
What is Jaguar Health, Inc. stock symbol ?
Jaguar Health, Inc. is a US stock , located in San francisco of Ca and trading under the symbol JAGX
What is Jaguar Health, Inc. stock quote today ?
Jaguar Health, Inc. stock price is $0.162 today.
Is Jaguar Health, Inc. stock public?
Yes, Jaguar Health, Inc. is a publicly traded company.
Company Profile
- Volume Average 45.24M
- Market Capitalization 18.67M
- Employee 49
- CEO Ms. Lisa A. Conte
- Headquarters San Francisco,CA,US
- IPO Date 2015-05-12
-
Website
https://jaguar.health 
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
